AstraZeneca and Oracle partner to explore AI and real-world data for clinical trial recruitment, drug-safety monitoring and hypertension care in Abu Dhabi.
Written By: Siddhi Bhadekar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
On 20 October 2026, AstraZeneca and Oracle Health and Life Sciences announced a global collaboration to explore how artificial intelligence (AI) and real-world data could improve clinical trial recruitment, support earlier diagnosis and strengthen drug-safety monitoring. The partnership combines AstraZeneca’s clinical development and regulatory expertise with Oracle’s data, cloud infrastructure and AI-enabled clinical capabilities.
The companies have signed a non-binding term sheet and disclosed no financial terms. The collaboration is intended to connect pharmaceutical research with routine healthcare delivery, although no clinical or operational outcomes have been reported.
Four Areas of Collaboration Across Five Therapeutic Groups
The partners will initially explore four areas: clinical trial recruitment, earlier diagnosis, drug-safety monitoring and real-world evidence generation across a medicine’s lifecycle.
The planned programmes will span oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare diseases. Projects are expected to involve the United States, the Middle East and Europe, with implementation shaped by local healthcare systems, governments and applicable regulations.
The collaboration aims to strengthen the links between research and routine care, potentially helping healthcare professionals identify eligible patients earlier and generate evidence that informs clinical development and treatment decisions.
Abu Dhabi Hypertension Programme to Lead Initial Work
The first programme will focus on hypertension care and clinical research in Abu Dhabi, in partnership with healthcare company M42. Its objectives are to identify patients with uncontrolled hypertension, support guideline-directed care and improve recruitment into clinical trials.
The programme will explore how clinical information and AI-enabled capabilities can help healthcare teams identify patients who may benefit from further clinical assessment or research participation. M42 has described an approach involving authorised research teams, professional review of potential patient matches and established consent procedures.
The initiative provides an initial setting for exploring how routine disease management and clinical research can operate more closely together. However, the companies have not disclosed its implementation timeline, target population, specific AI methods or recruitment targets.
Data Governance and Implementation
The collaboration will use deidentified real-world data under defined privacy, security and governance arrangements. AstraZeneca has stated that it will not receive patient-identifiable information. Each project will require separate legal, privacy, regulatory, ethical and institutional safeguards before proceeding.
These arrangements will be important as the partners explore applications across different healthcare systems and regions. The companies have not yet detailed the technical architecture or project-level performance measures.
Strategic Significance
The collaboration reflects an effort to use AI and real-world data beyond isolated research applications, linking patient identification, clinical trial recruitment, safety monitoring and routine care.
Its initial hypertension programme brings these objectives into a defined clinical setting, while the broader collaboration could extend the approach across AstraZeneca’s major therapeutic areas. Whether it improves recruitment efficiency, clinical decision-making or evidence generation will depend on the outcomes of individual projects.
For now, the agreement establishes a framework for collaboration rather than demonstrating clinical benefit. Further details on project implementation, timelines and measurable outcomes will be needed to assess its impact.
References
AstraZeneca and Oracle launch global AI collaboration to advance clinical trial optimisation and support better patient outcomes, Astra Zeneca, 20 October 2026
Oracle and AstraZeneca Partner to Advance AI-enabled Healthcare Innovation, Oracle, 20 October 2026
About the Writer
Siddhi Rajendra Bhadekar (Linkedin) is an M.Pharm professional with expertise in medical and scientific writing, literature review, publication writing, and evidence synthesis, supported by four peer-reviewed publications.
She brings working knowledge of ICH-GCP, MedDRA, pharmacovigilance, ADR/AE reporting, clinical data management, and regulatory documentation.
With experience across pharmaceutical R&D, Quality Control, and Quality Assurance, she combines scientific research skills with strong attention to accuracy and detail.
Her background in manuscript development, publication planning, and scientific communication enables her to translate complex healthcare information into clear, reliable content.